#### TRAINING UPDATE

Lab Location:SGMCDate Distributed:1/27/2017Department:Core LabDue Date:2/20/2017Implementation:2/20/2017

#### **DESCRIPTION OF PROCEDURE REVISION**

# Name of procedure:

# Myoglobin by Dimension Vista® System SGAH.C115 v2

# **Description of change(s):**

Section	Reason
3.2	Remove specimen onboard stability
4,5,6	Remove individual section labeling instructions and add general one
6.1, 6.2	Update QC material and storage
6.4, 6.5	Replace LIS with Unity Real Time
7.2	Specify freezer requirements by product
10.5	Move patient review from section 6
15	Update to new standard wording, Add reagent warning from section 4
17	Update QC product & insert dates

This revised SOP will be implemented on February 20, 2017

Document your compliance with this training update by taking the quiz in the MTS system.

# Technical SOP

Title	Myoglobin by Dimension Vista® System	n	
Prepared by	Ashkan Chini	Date:	6/25/2012
Owner	Robert SanLuis	Date:	2/4/2015

Laboratory Approval	Local Effective Date	:
Print Name and Title	Signature	Date
Refer to the electronic signature		
page for approval and approval		
dates.		

Review		
Print Name	Signature	Date

Form revised 2/02/2007

SOP ID: SGAH.C115 CONFIDENTIAL: Authorized for internal use only SOP Version # 2 Page 1 of 14

# TABLE OF CONTENTS

1.	Test Information	2
2.	Analytical Principle	3
3.	Specimen Requirements	3
4.	Reagents	4
5.	Calibrators/Standards	
6.	Quality Control	6
7.	Equipment And Supplies	
8.	Procedure	
9.	Calculations	10
10.	Reporting Results And Repeat Criteria	10
11.	Expected Values	11
12.	Clinical Significance	11
13.	Procedure Notes	12
14.	Limitations Of Method	12
15.	Safety	13
16.	Related Documents	13
17.	References	13
18.	Revision History	14
19.	Addenda	14

# 1. TEST INFORMATION

Assay	Method/Instrument	<b>Local Code</b>
Myoglobin	Dimension Vista® System	MYOGL

Synonyms/Abbreviations	
Myoglobin Quant, MYO	

Department	
Chemistry	

Form revised 2/02/2007

#### 2. ANALYTICAL PRINCIPLE

The MYO method is a homogeneous sandwich chemiluminescent immunoassay based on LOCI® technology. LOCI® reagents include two synthetic bead reagents and a biotinylated anti-myoglobin monoclonal antibody fragment. The first bead reagent (Sensibeads) is coated with streptavidin and contains photosensitizer dye. The second bead reagent (Chemibeads) is coated with an anti-myoglobin monoclonal antibody and contains chemiluminescent dye. Sample is incubated with Chemibeads and biotinylated antibody to form a bead-myoglobin-biotinylated antibody sandwich. Sensibeads are added and bind to form bead-pair immunocomplexes. Illumination of the complex by light at 680 nm generates singlet oxygen from Sensibeads which diffuses into the Chemibeads, triggering a chemiluminescent reaction. The resulting signal is measured at 612 nm and is a direct function of the myoglobin concentration in the sample.

# 3. SPECIMEN REQUIREMENTS

#### 3.1 Patient Preparation

Component	Special Notations
Fasting/Special Diets	N/A
Specimen Collection and/or Timing	Normal procedures for collecting and storing serum and plasma may be used for samples to be analyzed by this method.
Special Collection Procedures	N/A
Other	N/A

#### 3.2 Specimen Type & Handling

SOP Version #

Criteria	
Type -Preferred	Plasma (Heparin)
-Other Acceptable	Serum
<b>Collection Container</b>	Plasma: Mint green top tube (PST)
	Serum: Red top tube, Serum separator tube (SST)
Volume - Optimum	1.0 mL
- Minimum	0.5 mL
Transport Container and	Collection container or Plastic vial at room temperature
Temperature	
Stability & Storage	Room Temperature: 8 hours
Requirements	Refrigerated: 7 days
	Frozen: 28 days
Timing Considerations	Serum or plasma should be physically separated from cells
	as soon as possible with a maximum limit of two hours
	from the time of collection.

III 10 x 13 cd = 1 0 = 1 = 0 0 7

Page 3 of 14

Criteria	
<b>Unacceptable Specimens</b>	Specimens that are unlabeled, improperly labeled, or those
& Actions to Take	that do not meet the stated criteria are unacceptable.
	Request a recollection and credit the test with the
	appropriate LIS English text code for "test not performed"
	message. Examples: Quantity not sufficient-QNS; Wrong
	collection-UNAC. Document the request for recollection in
	the LIS.
<b>Compromising Physical</b>	Gross hemolysis. Reject sample and request a recollection.
Characteristics	Credit the test with the appropriate LIS English text code
	explanation of HMT (Specimen markedly hemolyzed)
Other Considerations	Allow Red Top or SST to clot completely prior to
	centrifugation.

NOTE: Labeling requirements for all reagents, calibrators and controls include: (1) Open date, (2) Substance name, (3) Lot number, (4) Date of preparation, (5) Expiration date, (6) Initials of tech, and (7) Any special storage instructions. Check all for visible signs of degradation. When placed onboard the analyzer, the instrument captures the date / time loaded and calculates and tracks the opened expiration.

#### 4. REAGENTS

The package insert for a new lot of kits must be reviewed for any changes before the kit is used. A current Package Insert is included as a Related Document.

# 4.1 Reagent Summary

Reagents	Supplier & Catalog Number
Myoglobin	Siemens, Flex® reagent cartridge, Cat. No. K6422

### 4.2 Reagent Preparation and Storage

Reagent	Myoglobin
Container	Reagent cartridge
Storage	Store at 2-8° C
Stability	<ul> <li>Reagent is stable until expiration date stamped on the reagent cartridges.</li> <li>Sealed wells on the instrument are stable for 30 days.</li> <li>Once wells 1 - 12 have been entered by the instrument, they are stable for 7 days.</li> </ul>
Preparation	All reagents are liquid and ready to use.

orm revised 2/02/2007

SOP ID: SGAH.C115 CONFIDENTIAL: Authorized for internal use only SOP Version # 2 Page 4 of 14

### 5. CALIBRATORS/STANDARDS

### 5.1 Calibrators/Standards Used

Calibrator	Supplier and Catalog Number
MYO CAL	Siemens Dimension Vista®, Cat. No. KC624

# **5.2** Calibrator Preparation and Storage

Calibrator	MYO CAL
Preparation	Before use, thaw at room temperature (22-28°C), swirl and
	invert gently to mix.
Storage/Stability	• Store at -15°C to -25°C
	• <b>Unopened (frozen) calibrator</b> is stable until expiration date stamped on the box.
	• <b>Unopened thawed calibrator</b> is stable for 30 days when stored at 2-8°C. Do not re-freeze.
	• <b>Opened Calibrator:</b> once the stopper of the vial is punctured, assigned values are stable for 7 days when stored on board the Dimension Vista System.
	• <b>Opened Calibrator:</b> once cap is removed, assigned values are stable for 30 days when recapped immediately after use and stored at 2-8°C. <b>Do not use this vial on board the</b>
	instrument.

#### **5.3** Calibration Parameter

Criteria	Special Notations	
Reference Material	MYO CAL	
Assay Range	1-1000  ng/mL	
Suggested Calibration Level	See Reagent Package Insert for lot specific assigned values in ng/mL	
Frequency	<ul> <li>Every new reagent cartridge lot.</li> <li>Every 30 days for any one lot</li> <li>When major maintenance is performed on the analyzer.</li> <li>When control data indicates a significant shift in assay.</li> </ul>	
Calibration Scheme	6 levels, n = 3	

#### **5.4** Calibration Procedure

#### **Auto Calibration:**

- 1. Place the required calibrator vials in a carrier. Make sure the barcode labels are entirely visible through the slots.
- 2. Place the carrier in the loading area.

- 3. Position the carrier with the labels facing away from the user.
- 4. Press the **Load** button.
- 5. Automatic calibration requires that calibrators be on the instrument. As the time for processing approaches, the instrument reviews onboard inventory for the appropriate calibrators.

#### **Manual Calibration:**

- 1. Verify that calibrators and reagents are in inventory on the instrument.
- 2. Press **System > Method Summary > Calibration**.
- 3. Select a method from the sidebar menu. Press the **Order Calibration** button on the screen.
- 4. Verify that the information on the screen is correct. Verify that the calibrator lot is correct using the drop-down menu.
  - a. When calibrating using Vials press **OK**.
  - b. When calibrating using Cups, check the Use Cups box. This displays the rack and cup position fields. For additional cups use the positions in ascending order. Be sure to use the number of calibration levels and cups as specified in the method IFU. Scan the rack barcode and place calibrator cups in an adapter in position 1 on a rack. Press **OK** and load the rack on the instrument.
- 5. The status field in the calibration screen changes sequentially to Awaiting Scheduling, Preparing Calibrators and Processing.

#### **5.5** Tolerance Limits

IF	THEN
If result fall within assay-specific specification,	proceed with analysis
and QC values are within acceptable limits,	
If result falls outside assay-specific specification,	troubleshoot the assay and/or
or QC values are out of Acceptable limits,	instrument and repeat calibration

#### 6. QUALITY CONTROL

#### **6.1** Controls Used

Controls	Supplier and Catalog Number
	Bio-Rad Laboratories
Levels 1C, 2 and 3	Cat # <mark>297, 298 and 299</mark>

### **6.2** Control Preparation and Storage

Control	Liquichek Cardiac Markers Plus Control LT, Level 1C, 2 and 3
Preparation	Allow the frozen control to thaw at room temperature (18-25°C)
	for approximately 30 minutes or until completely thawed. Swirl
	the contents gently to ensure homogeneity. (Do not use a
	mechanical mixer). Immediately load the vial on the analyzer.

SOP ID: SGAH.C115 CONFIDENTIAL: Authorized for internal use only SOP Version # 2 Page 6 of 14

	After each use, promptly replace the stopper and return to 2-8°C storage.
Storage/Stability	Frozen controls are stable until the expiration date at -20 to -50° C.
	<u>Thawed and unopened</u> : When stored unopened at 2-8°C and the stopper is not punctured on-board the Siemens Dimension
	Vista, all analytes will be stable for 10 days.
	<u>Thawed and opened</u> : Once the stopper is punctured, all analytes will be stable for 10 days when stored at 2- 8°C.
	Once thawed, do not re-freeze

# 6.3 Frequency

Analyze all levels of QC material after every calibration and each day of testing (notated on the QC frequency sheets posted on the instruments).

Refer to the Dimension Vista® QC Schedule in the Laboratory policy Quality Control Program and in the Dimension Vista® Quick Reference Guide.

### **6.4** Tolerance Limits

Step	Action
1	Acceptable ranges for QC are programmed into the instrument's Quality Control software system and Unity Real Time, and may be posted near the instrument for use during computer downtime.
2	<ul> <li>Run Rejection Criteria</li> <li>Anytime the established parameters are exceeded (if one QC result exceeds 2 SD), the run is considered out of control (failed) and patient results must not be reported.</li> <li>The technologist must follow the procedure in the Laboratory QC Program to resolve the problem.</li> </ul>
3	Corrective Action:  All rejected runs must be effectively addressed through corrective action. Steps taken in response to QC failures must be documented. Patient samples in failed analytical runs must be reanalyzed according to the Laboratory QC Program. Supervisors may override rejection of partial or complete runs only with detailed documentation and criteria for overrides that are approved by the Medical Director. Consult corrective action guidelines in Laboratory QC Program. Follow corrective action guidelines in the Laboratory QC Program.
	• Corrective action documentation must follow the Laboratory Quality Control Program.

SOP ID: SGAH.C115

Step	Action	
4	Review of QC	
	QC must be reviewed weekly by the Group Lead or designee and monthly by the Supervisor/Manager or designee.	
	• If the SD and/or CV are greater than established ranges, investigate the cause for the imprecision and document implementation of corrective actions.	

#### 6.5 Documentation

- QC tolerance limits are programmed into the instrument and Unity Real Time; it calculates cumulative mean, SD and CV and stores all information for easy retrieval.
- Quality control records are reviewed daily at the bench, weekly by the Group Lead or designee, and monthly by the Supervisor/Manager or designee.
- Refer to complete policies and procedures for QC documentation and for record retention requirements in the Laboratory QC Program.

### 6.6 Quality Assurance Program

- Each new lot number of reagent or new shipment of the same lot of reagent must be tested with external control materials and previously analyzed samples.
   Performance of the new lot must be equivalent to the previous lot; utilize published TEA for acceptability criteria.
- Training must be successfully completed and documented prior to performing this
  test. This procedure must be incorporated into the departmental competency
  assessment program.
- The laboratory participates in CAP proficiency testing. All proficiency testing materials must be treated in the same manner as patient samples.
- Monthly QC must be presented to the Medical Director or designee for review and signature.
- Monthly QC mean and SD are sent to Bio-Rad Laboratories for peer group comparison.
- Consult the Laboratory QC Program for complete details.

#### 7. EQUIPMENT and SUPPLIES

#### 7.1 Assay Platform

Dimension Vista® System

#### 7.2 Equipment

• Refrigerator capable of sustaining 2–8°C

TOTHLICKISCH PLOTEROOF

- Freezer capable of sustaining range not to exceed -15 to -25°C for calibrator
- Freezer capable of sustaining range not to exceed -20 to -50°C for QC product
- Centrifuge

### 7.3 Supplies

- Aliquot Plates
- System Fluids
- Assorted calibrated pipettes (MLA or equivalent) and disposable tips

#### 8. PROCEDURE

MYO Flex® reagent cartridge Cat. No. K6422 is required to perform this test.

Myoglobin is performed on the Dimension Vista<sup>®</sup> System after the method is calibrated (see Reference Material in Calibration section) and Quality Controls are acceptable.

NOTE: For all procedures involving specimens, buttoned lab coats, gloves, and face protection are required minimum personal protective equipment. Report all accidents to your supervisor.

8.1	Sample Processing
1.	A sample rack holding tubes or cups is placed on the rack input lane.
2.	The sample shuttle moves the rack to the barcode reader which identifies the rack and samples to the system.
3.	The rack moves into the sample server and to the rack positioner.
4.	At the same time, aliquot plates move from the aliquot loader into position.
5.	The aliquot probe aspirates the sample from the tubes or cups and dispenses it into the wells of the aliquot plates.
6.	After each aspirate-dispense action, the probe is thoroughly rinsed inside and out to prevent sample carryover.
7.	When sample aspiration is completed, the sample server moves the rack back to the sample shuttle, where it is placed on the output lane and can be removed by the operator.
	operator.

8.2	Specimen Testing
1.	For QC placement and frequency, refer to the Dimension Vista® QC Schedule in the Laboratory QC Program.
2.	Follow the instructions, outlined in the Dimension Vista® Operator's Manual
3.	The instrument reporting system contains error messages to warn the user of specific malfunctions. Results followed by such error messages should be held for follow-up. Refer to the Dimension Vista® system manual "Error messages" section for troubleshooting.

TCA12CR 7/ 07/ 700/

8.2	Specimen Testing		
4.	Follow protocol in Section 10.5 "Repeat criteria and resulting" for samples with results above or below the Analytical Measurement Range (AMR).		
	Investigate any failed delta result and repeat, if necessary.		
5.	Append the appropriate English text code qualifier messages to any samples requiring a comment regarding sample quality and/or any other pertinent factors.		

Test Conditions			
Sample Volume:	2 μL		
Chemibead Reagent Volume:	30 μL		
Biotinylated Antibody Volume:	30 μL		
Sensibead Volume:	20 μL		
Assay Buffer Volume:	70 μL		
Reaction Time:	10 minutes		
Test Temperature:	37° C		
Wavelength:	680 and 612 nm		
Type of measurement:	Chemiluminescence		

NOTE: In the event that the test system becomes inoperable, notify supervision or designee for further direction. Patient specimens must be stored in a manner that maintains the integrity of the specimen.

### 9. CALCULATIONS

The instrument automatically calculates the concentration of Myoglobin in ng/mL.

#### 10. REPORTING RESULTS AND REPEAT CRITERIA

### 10.1 Interpretation of Data

None required

### 10.2 Rounding

No rounding is necessary. Instrument reports results as a whole number.

#### 10.3 Units of Measure

ng/mL

### 10.4 Clinically Reportable Range (CRR)

1 - 20,000 ng/mL

#### 10.5 Review Patient Data

Each result is reviewed for error messages. Refer to the Dimension Vista system manual "Error messages" section for troubleshooting. Resolve any problems noted before issuing patient reports.

#### 10.6 Repeat Criteria and Resulting

All repeats must replicate the original result within the total allowable error (TEa) of the assay. Refer to TEa listing for specific information.

Values that fall within the AMR or CRR may be reported without repeat. Values that fall outside these ranges must be repeated.

IF the result is	THEN		
< 1 ng/mL	Assure there is sufficient sample devoid of bubbles, cellular		
	debris, and/or fibrin clots. Report as:		
	< 1 ng/mL		
	On Board Automated Dilution:		
$\geq 1000 \text{ ng/mL}$	Results ≥ 1000 ng/mL will automatically have repeat testing		
	performed into the instrument using dilution factor of 20.		
	No multiplication is necessary.		
	If the recommended dilution does not give results within the		
> 20,000  ng/mL	clinically reportable range, report as: "> 20,000 ng/mL-REP"		
	Bring to the attention of your supervisor prior to releasing		
	result.		

Message	Code	
Verified by repeat analysis	Append –REP to the result.	

#### 11. EXPECTED VALUES

#### 11.1 Reference Ranges

10 - 92 ng/mL

#### 11.2 Critical Values

None established

### 11.3 Standard Required Messages

None established

#### 12. CLINICAL SIGNIFICANCE

SOP Version #

Myoglobin is a heme protein found in both cardiac and skeletal muscle cells and is released

Form revised 2/02/2007

Page 11 of 14

SOP ID: SGAH.C115 CONFIDENTIAL: Authorized for internal use only

in the serum when damage occurs to these cells. In the absence of skeletal muscle trauma or other factors associated with non-cardiac related increase in circulating myoglobin, myoglobin levels have been used as an early marker for detection of myocardial infarction (MI). Following myocardial necrosis associated with MI, myoglobin is one of the first markers to rise above normal levels, increasing measurably above baseline within 1–3 hours post infarct, peaking at 6–12 hours and returning to baseline within 24–36 hours. Reports suggest the measurement of myoglobin as an aid in risk stratification of chest pain patients and as an aid in the diagnosis of myocardial infarction. Negative predictive values for myocardial infarction of up to 100% have been reported at certain periods after the onset of symptoms.

#### **13.** PROCEDURE NOTES

• **FDA Status:** FDA Approved/cleared Validated Test Modifications: None

The instrument reporting system contains error messages to warn the operator of specific malfunctions. Any report slip containing such error messages should be held for follow-up. Refer to your Dimension Vista Operator's Guide.

The expected maximum observed standard deviations for repeatability using n = 5 replicates at the following Myoglobin concentrations are:

MYO Concentration	Acceptable S.D. Maximum
110 ng/mL	24 ng/mL
367 ng/mL	75 ng/mL

#### 14. LIMITATIONS OF METHOD

#### 14.1 **Analytical Measurement Range (AMR)**

1-1000 ng/mL

#### 14.2 Precision

	Mean	Standard Deviation (%CV)		
Material	ng/mL	Repeatability	Within-Lab	
Liquichek Cardiac Control				
Level 1	113	2.7 (2.4)	4.0 (3.6)	
Serum Pool Level 1	110	5.4 (4.9)	5.5 (5.0)	
Serum Pool Level 2	502	17.3 (3.4)	18.7 (3.7)	
Serum Pool Level 3	831	23.1 (2.8)	27.6 (3.3)	

#### 14.3 Interfering Substances

CONFIDENTIAL: Authorized for internal use only

#### **HIL Interference:**

The MYO method was evaluated for interference according to CLSI/NCCLS EP7-A2. Bias, defined as the difference between the control sample (does not contain interferent) and the test sample (contains interferent), is shown in the table below. Bias exceeding 10% is considered "interference".

Substance tested	<b>Substance Concentration</b>	MYO ng/mL	Bias %
Hemoglobin (hemolysate)	1000 mg/dL	120	<10
Bilirubin (unconjugated)	60 mg/dL	100	<10
Bilirubin (conjugated)	60 mg/dL	98	<10
Lipemia Intralipid®	3000 mg/dL	94	<10

#### 14.4 Clinical Sensitivity/Specificity/Predictive Values

Not available

#### 15. **SAFETY**

Refer to your local and corporate safety manuals and Safety Data Sheet (SDS) for detailed information on safety practices and procedures and a complete description of hazards.

MYO Flex® Reagent Cartridge may cause an allergic skin reaction.

Wear protective gloves/protective clothing/eye protection/face protection. Contaminated work clothing should not be allowed out of the workplace. IF ON SKIN: Wash with plenty of soap and water. If skin irritation or rash occurs: Get medical advice/attention

#### **16.** RELATED DOCUMENTS

- 1. Dimension Vista<sup>®</sup> Clinical Chemistry System Operator's Manual
- Dimension Vista<sup>®</sup> Calibration/Verification Procedure
   Dimension Vista<sup>®</sup> Cal Accept Guidelines
- 4. Dimension Vista<sup>®</sup> Calibration summary
- 5. Dimension Vista® Sample Processing, Startup and Maintenance procedure
- 6. Laboratory Quality Control Program
- 7. QC Schedule for Siemens Dimension Vista®
- 8. Laboratory Safety Manual
- 9. Safety Data Sheets (SDS)
- 10. Dimension Vista® Limits Chart (AG.F200)
- 11. Quest Diagnostics Records Management Procedure
- 12. Dimension Vista® System Error Messages Chart
- 13. Centrifuge Use, Maintenance and Function Checks (Lab policy)
- 14. Hemolysis, Icteria and Lipemia Interference (Lab policy)
- 15. Repeat Testing Requirement (Lab policy)
- 16. Current Allowable Total Error Specifications at http://questnet1.qdx.com/Business\_Groups/Medical/qc/docs/qc\_bpt\_tea.xls
- 17. Current package insert MYO Flex® Reagent Cartridge K6422

#### 17. REFERENCES

- 1. Package Insert, MYO Flex<sup>®</sup> Reagent Cartridge K6422, Siemens Healthcare Diagnostics Inc., 2/24/2015.
- 2. Package Insert, MYO CAL, Siemens Healthcare Diagnostics Inc., 01/2015.
- 3. Package Insert, Liquichek Cardiac Markers Plus Control LT, Bio-Rad Laboratories, 12/2015.

#### 18. REVISION HISTORY

Version	Date	Section	Reason	Reviser	Approval
000	2/4/15		Update owner	L Barrett	R SanLuis
000	2/4/15	5.2	Change in frozen storage temperature	L Barrett	R SanLuis
000	2/4/15	7.2	Change freezer requirements	L Barrett	R SanLuis
000	2/4/15	Footer	Version # leading zero's dropped due to new EDCS in use as of 10/7/13	L Barrett	R SanLuis
1	1/19/17	3.2	Remove specimen onboard stability	L Barrett	R SanLuis
1	1/19/17	4,5,6	Remove individual section labeling instructions and add general one	L Barrett	R SanLuis
1	1/19/17	6.1, 6.2	Update QC material and storage	L Barrett	R SanLuis
1	1/19/17	6.4, 6.5	Replace LIS with Unity Real Time	L Barrett	R SanLuis
1	1/19/17	7.2	Specify freezer requirements by product	L Barrett	R SanLuis
1	1/19/17	10.5	Move patient review from section 6	L Barrett	R SanLuis
1	1/19/17	15	Update to new standard wording, add reagent warning	L Barrett	R SanLuis
1	1/19/17	17	Update QC product & insert dates	L Barrett	R SanLuis

#### 19. ADDENDA

None

Form revised 2/02/2007

SOP ID: SGAH.C115 CONFIDENTIAL: Authorized for internal use only SOP Version # 2 Page 14 of 14